Navigation Links
New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings

n of TLR in small vessels (2.9 percent versus 4.8 percent in vessels less than 2.8 mm in diameter; p=0.046) compared to the Taxus Stent.

In the United States, the CYPHER(R) Stent is indicated for previously untreated lesions that are less than 30 mm in length with a reference vessel diameter ranging from more than 2.50 mm to less than 3.50 mm.

"Studies have shown that TLR is not benign. These registry findings provide additional assurance to the interventional cardiology community regarding the efficacy of the CYPHER(R) Stent to prevent the need for repeat revascularizations in a real-world clinical setting," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Cardiology Division of Cordis Corporation.

About the CYPHER(R) Stent

The CYPHER(R) Stent has been chosen by cardiologists worldwide to treat approximately three million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER(R) Stent in a broad range of patients.

Developed and manufactured by Cordis Corporation, the CYPHER(R) Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. The next version of sirolimus-eluting stent, the CYPHER(R) SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER(R) SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets outside the United States.

For more complete information on indications, contraindications, warnings and precautions, see the Instructions for Use available at www.cypherstent.com.

About Cord
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/23/2015)... VEGAS , Jan. 23, 2015 Cord Blood America, ... ) ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, ... www.sec.gov ) today, and provides an update for shareholders detailing ... shares is requested. Dear Shareholders, As ...
(Date:1/23/2015)... BIRMINGHAM, Ala. , Jan. 23, 2015 Gem ... (STS) patients have been enrolled into the Company,s Phase ... efficacy and safety of Gem,s lead compound, GPX-150 (an ... for advanced or metastatic disease. Logo - ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Oct. 21 The U.S. Food and Drug ... been added to the label for the HIV ... effects on the heart when used with Norvir ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ...
... 21 Span-America Medical Systems, Inc. (Nasdaq:  SPAN) will ... conference call on Tuesday, November 2, 2010, covering results ... be released after the regular close of trading the ... conference call will be available online at  www.spanamerica.com ...
Cached Medicine Technology:New Label Changes for Commonly Prescribed HIV Drug Invirase 2
(Date:1/22/2015)... 22, 2015 Padre Murphy's and Owner Tom ... Pro Player Health Alliance (PPHA). The PPHA's passion ... getting everyone, including NFL greats, treated for obstructive sleep apnea ... groups supporting the cause in the valley. The most recent ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... Feb. 20 When Avaya rolls its,18-wheel ... floor of HIMSS08,next week, onboard will be ... are helping healthcare organizations address critical,communications challenges ... a leading global provider of business communications ...
... announced that, due to continuing declines in Portamedic revenues,the ... fourth quarter 2007,excluding the gain on sale of its ... to a greater than expected,reduction in paramedical exams of ... year. Regarding 2008, the Company no longer expects to ...
... MacuSight(TM), Inc., a,developer of innovative therapeutics for ... announced the appointment of Joel Naor,M.D., M.Sc., MBA, ... in the clinical development of therapeutics for ocular ... role in MacuSight,s ongoing,advancement of its sirolimus program, ...
... Feb. 20 IDM Pharma, Inc.,(Nasdaq: IDMI ) ... Market that the Company has regained compliance with NASDAQ,Marketplace ... bid price of at least $1.00 per share., ... Company,s common stock,was $3.14 per share., About IDM ...
... Featured At Premier Las Vegas Training Facility, ... global,leader in dental and aesthetic lasers, today announced ... Dental Studies (LVI), an,internationally recognized leader in post-graduate ... lasers will be utilized at,LVI,s state-of-the-art teaching facility ...
... finds anxiety over financial, preparedness; consumers say health care ... ... WASHINGTON, Feb. 20 American consumers want more from,their health ... care providers and medical records, customized,insurance coverage and wider access to ...
Cached Medicine News:Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 2Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 3Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 4Health News:Hooper Holmes Updates Guidance 2Health News:Hooper Holmes Updates Guidance 3Health News:MacuSight Expands Management Team With Appointment of Dr. Joel Naor as Chief Medical Officer 2Health News:IDM Pharma Announces Compliance With NASDAQ Minimum Bid Price Requirements 2Health News:HOYA ConBio Announces Educational Agreement With LVI Global 2Health News:Groundbreaking Deloitte Survey Reveals Many U.S. Consumers Want Major Changes in Health Care Design, Delivery 2Health News:Groundbreaking Deloitte Survey Reveals Many U.S. Consumers Want Major Changes in Health Care Design, Delivery 3Health News:Groundbreaking Deloitte Survey Reveals Many U.S. Consumers Want Major Changes in Health Care Design, Delivery 4
... These corrosion proof polypropylene exhaust hoods ... edge of tanks and draw a stream ... tank away from the operator. Other sizes ... semi-canopy, lateral, and double-slot are available on ...
These handy dispensers save space and organize gloves in labs and next to hand washers. Static-dissipative PVC eliminates static charges and the particles they attract . Many other sizes and custom c...
... base sliding microtome offers the ultimate in ... not least, safety. ,Designed to meet the ... 8000 will also meet the more demanding ... versatility and wide range of accessories will ...
... Starter Package is a solid ... laboratory. The package includes the ... additional mounting blocks, v-block adapter, ... a rotating stage assembly for ...
Medicine Products: